Oligonucleotide, Primer, and Probe Supplier Qualification for IVD Molecular Diagnostics

Oligonucleotides Are the Most Precise and Most Fragile Raw Material in Your IVD Kit

Every molecular diagnostic test — PCR, RT-qPCR, dPCR, LAMP, CRISPR-based detection, NGS-based panels — depends on oligonucleotides. Primers define what gets amplified. Probes define what gets detected. A single base error, a truncated product, a contaminating sequence, or an impurity from incomplete synthesis can cause a false negative on a clinical sample, elevate background signal across an entire kit lot, or introduce cross-reactivity that your assay design never anticipated.

The precision requirement is extraordinary. A primer pair for a qPCR assay targeting a specific pathogen gene must amplify only the intended target with no cross-reactivity against the entire human genome, the genomes of related pathogens, and any nucleic acid sequences that might be present in the clinical sample matrix. A TaqMan probe must hybridize with exactly the right melting temperature, fluoresce at the right wavelength, and quench efficiently in the intact state. These performance characteristics depend entirely on the quality of the oligonucleotide — its sequence accuracy, its purity from synthesis byproducts, its modification integrity, and its freedom from contamination.

Yet the oligonucleotide supply chain is fragmented and tiered in ways that many IVD manufacturers do not fully understand. The same sequence can be ordered from dozens of suppliers at prices that vary by 10-fold, and the quality differences between a $5 research-grade primer and a $50 IVD-grade primer with full documentation are invisible on a gel but decisive in a diagnostic assay. This guide covers how to navigate the oligonucleotide supplier landscape, how to qualify suppliers for IVD manufacturing, and how to manage the ongoing quality of this critical raw material.

Understanding Oligonucleotide Quality Grades

The oligonucleotide market is segmented into quality grades that reflect different levels of manufacturing control, documentation, and regulatory alignment. Understanding these grades is the first step in supplier selection.

Research Grade (ISO 9001)

Research-grade oligonucleotides are synthesized under an ISO 9001:2015-certified quality management system. This provides a general framework for product development, manufacturing, and delivery. The quality controls typically include:

• Mass spectrometry verification (MALDI-TOF for shorter oligos, ESI-MS for longer ones)
• Basic purity assessment (OD measurement, desalting)
• Standard or optional HPLC purification
• Certificate of Analysis with basic lot data

Research-grade oligos are appropriate for early-stage assay development, screening, and feasibility work. They are not appropriate for use in IVD kits that will be sold commercially, because the manufacturing controls and documentation do not meet medical device regulatory requirements.

IVD/Commercial Grade (ISO 13485)

IVD-grade oligonucleotides are manufactured under an ISO 13485-certified quality management system, which is the quality standard required for medical device manufacturing. This certification means the supplier has:

• Documented procedures for manufacturing control, change management, and traceability
• Validated manufacturing processes with documented evidence of reproducibility
• Complete batch records with full traceability of raw materials and process parameters
• Change notification obligations to customers
• Capability for audit by customers and regulatory authorities

Suppliers like LGC Biosearch Technologies, Microsynth, Eurogentec, and Thermo Fisher Scientific offer IVD-grade oligonucleotide manufacturing under ISO 13485 certification. These suppliers manufacture in classified cleanroom environments (ISO 7 and ISO 8 for diagnostic-grade production), provide Certificates of Analysis with full batch traceability, and maintain change control procedures aligned with medical device regulatory requirements.

GMP Grade

GMP-grade oligonucleotides represent the highest tier of manufacturing control, with fully validated processes, comprehensive documentation, and regulatory filing support. Suppliers like IDT and Thermo Fisher Scientific offer GMP oligo manufacturing services with dedicated GMP manufacturing suites. GMP-grade oligos are typically required for therapeutic applications but may also be specified for high-risk IVD assays or when the oligonucleotide itself is the active component (e.g., analyte-specific reagents).

What Grade Do You Actually Need for IVD Kits?

For most IVD kits, ISO 13485-grade oligonucleotides are the appropriate starting point. The ISO 13485 certification provides the manufacturing control, documentation, and change notification framework that aligns with IVD regulatory requirements. GMP-grade oligonucleotides may be warranted for Class C or Class D IVDs under IVDR, for companion diagnostics, or for assays where the oligonucleotide is the primary active ingredient.

The key principle is that the quality grade must match the risk level and regulatory requirements of the finished device. Using research-grade oligonucleotides in a commercial IVD kit creates a regulatory gap that will be identified during notified body audit or FDA inspection.

Oligonucleotide Synthesis: Where Quality Is Built and Where It Can Fail

Understanding the synthesis process helps you evaluate suppliers and interpret quality data.

Solid-Phase Phosphoramidite Synthesis

Nearly all custom oligonucleotides are manufactured by solid-phase phosphoramidite synthesis, a cyclical process that builds the oligonucleotide one nucleotide at a time on a solid support (controlled pore glass or polystyrene). Each synthesis cycle involves four steps: detritylation (removing the protecting group from the previous base), coupling (adding the next phosphoramidite), capping (blocking unreacted sequences to prevent deletions), and oxidation (stabilizing the phosphate backbone).

The critical quality parameter of the synthesis process is the coupling efficiency at each step — the percentage of growing chains that successfully receive the next nucleotide. If the coupling efficiency is 99% at each step, a 25-mer oligonucleotide will have approximately 78% full-length product. If it drops to 98%, only about 60% will be full-length. For longer oligonucleotides or heavily modified probes, the impact compounds further.

Coupling efficiency depends on phosphoramidite quality, synthesizer condition, moisture control, and reagent freshness. This is why the quality of the phosphoramidite raw material matters: Thermo Fisher Scientific's TheraPure phosphoramidite line, for example, specifies HPLC purity of 99% or higher with defined impurity specifications, compared to 98% for standard-grade phosphoramidites. The water content specification (0.3% or lower for TheraPure) is critical because moisture is the primary enemy of coupling efficiency in phosphoramidite chemistry.

Purification Methods and Their Impact on IVD Performance

After synthesis, the crude oligonucleotide contains a mixture of full-length product and truncated failure sequences (primarily N-1, N-2, etc., where one or more nucleotides are missing). The purification method determines the final purity level:

Desalting (salt-free). Removes small-molecule impurities and excess salts from the synthesis process but does not remove truncated failure sequences. Purity is typically 50-80% full-length product depending on oligo length. Adequate for routine PCR primers in non-critical applications, but generally insufficient for IVD probe manufacturing.

HPLC purification. Reverse-phase (RP) HPLC separates based on hydrophobicity (trityl-on purification takes advantage of the hydrophobic trityl group on full-length product), while ion-exchange (IE) HPLC separates based on charge. HPLC purification can achieve >85-95% full-length product. The Waters OST (Oligonucleotide Separation Technology) column platform is widely used for analytical and preparative oligonucleotide purification, providing quality control-tested columns specifically designed for oligonucleotide analysis.

PAGE purification. Polyacrylamide gel electrophoresis separates based on size, effectively removing truncation products. Can achieve ~90% or higher purity. More labor-intensive and lower-yielding than HPLC, but effective for longer oligonucleotides where HPLC resolution is limited.

Dual purification (HPLC + PAGE). Combines both methods for the highest purity levels (>90-95%). Used for critical applications such as TaqMan probes, molecular beacons, and other modified oligonucleotides where purity directly impacts assay performance.

Why Purity Matters for IVD Performance

For PCR primers, truncated failure sequences compete with full-length primers for binding sites but cannot support productive amplification. This effectively reduces the concentration of functional primer in the reaction, which can shift the amplification efficiency and affect quantification accuracy in qPCR assays. For heavily multiplexed assays, where multiple primer pairs compete for resources, the impact of impure primers is amplified because the non-functional truncated primers still consume reagents (dNTPs, enzyme activity) without contributing to signal.

For TaqMan probes and other dual-labeled oligonucleotides, impurities are even more consequential. A truncated probe that retains the fluorophore but lacks the quencher (because the truncation occurred at the quencher attachment site) will produce constant fluorescence, elevating background and reducing the signal-to-noise ratio of the assay. Conversely, a probe that retains the quencher but lacks the fluorophore will compete with full-length probe for target binding without generating signal, effectively reducing the functional probe concentration. Both scenarios degrade assay sensitivity.

Supplier Qualification Process

Step 1: Supplier Assessment

Quality system. Verify ISO 13485 certification scope covers oligonucleotide manufacturing for IVD applications. Confirm that the certification covers the specific manufacturing site that will produce your oligonucleotides (some suppliers have multiple sites with different certifications). LGC Biosearch Technologies, for example, operates ISO 9001 and ISO 13485 manufacturing facilities in Denmark and the USA, providing multi-site redundancy and manufacturing risk mitigation.

Manufacturing capabilities. Evaluate:

• Synthesis scale: Can the supplier produce at your required scale (from nanomoles for development to millimoles for commercial supply)?
• Modification capabilities: Does the supplier support the full range of modifications you need (fluorophores, quenchers, locked nucleic acids, 2'-O-methyl RNA, phosphorothioate linkages, MGB moieties, amino modifiers)?
• Purification options: Can the supplier provide the required purity level (HPLC, PAGE, dual purification) with validated methods?
• Cleanroom classification: Is synthesis, purification, and packaging performed in classified cleanroom space?
• Contamination control: What procedures are in place to prevent cross-contamination between sequences? This is particularly important for IVD oligonucleotide manufacturing, where contaminating sequences from a previous synthesis run could produce false positive signals in the final diagnostic assay.

Documentation capabilities. Confirm the supplier can provide:

• Certificates of Analysis with lot-specific test data
• Analytical data packages (mass spectra, HPLC chromatograms, CE electropherograms) upon request
• Batch traceability documentation
• Stability data supporting assigned shelf life
• Change notification per agreed timelines
• Regulatory support documentation (DMF references, site quality self-assessments)

References and track record. Evaluate the supplier's experience supporting IVD manufacturers. Suppliers who primarily serve academic research may lack the documentation rigor, change control maturity, and customer support infrastructure needed for regulated manufacturing.

Step 2: Specification Development

Develop a comprehensive incoming material specification for each oligonucleotide used in your IVD kit. The specification should address:

Identity. Sequence confirmation by mass spectrometry. ESI-MS is preferred over MALDI-TOF for longer oligonucleotides because it maintains accuracy up to 200 nucleotides, while MALDI-TOF becomes less accurate beyond 40 nucleotides. For mixed-base oligonucleotides where multiple masses are present, identity confirmation may need to rely on alternative methods or partial sequence verification.

Purity. Full-length product percentage as measured by capillary electrophoresis (CE) or analytical HPLC. Specify the minimum acceptable purity based on the oligonucleotide's role in the assay:

• Standard PCR primers: ≥85% full-length (HPLC-purified)
• qPCR primers in quantitative assays: ≥90% full-length
• TaqMan probes and dual-labeled oligonucleotides: ≥90-95% full-length (HPLC or dual-purified)
• Long oligonucleotides (>60 nt): ≥80% full-length (length-adjusted, recognizing that coupling efficiency compounds over more cycles)

Modifications. Verification that all modifications are present and correctly positioned. For dual-labeled probes, this means confirming both fluorophore and quencher attachment. For modified bases (LNA, 2'-O-Me), confirming correct placement in the sequence. Analytical methods include UV-Vis spectroscopy (for fluorophore absorbance), HPLC retention time comparison to reference, and mass spectrometry.

Concentration/yield. UV absorbance at 260 nm (A260) with extinction coefficient calculated from the specific sequence and modifications. Report both the total yield and the concentration in the supplied formulation.

Contamination control. For IVD-grade oligonucleotides, test for:

• Template contamination: E. coli genomic DNA, human genomic DNA, and any other potential template sources that could produce false positive amplification. Some suppliers, like Eton Bioscience, provide contamination control documentation including E. coli and human DNA contamination testing for every lot.
• Cross-contamination: Sequences from previous synthesis runs on the same synthesizer. Prevention requires rigorous washing protocols between runs and physical separation of synthesis, cleavage/deprotection, and purification operations.
• Nuclease contamination: DNase and RNase activity testing for oligonucleotides that will be used in sensitive downstream applications.

Storage and formulation. Specify the storage buffer (typically TE buffer, 10 mM Tris-HCl pH 8.0, 0.1 mM EDTA, or lyophilized), the storage temperature, and the reconstitution procedure if supplied lyophilized.

Step 3: Qualification Testing

Qualify each oligonucleotide from a new supplier through a structured testing program:

Independent analytical verification. Don't rely solely on the supplier's CoA. Perform your own analytical testing:

• Verify identity by mass spectrometry (compare observed mass to calculated mass)
• Verify purity by analytical HPLC or CE
• Verify modification integrity by UV-Vis or HPLC
• Measure concentration by A260 with sequence-specific extinction coefficient

Functional performance testing in the assay. This is the most important qualification step. Manufacture a pilot kit lot using the oligonucleotides from the candidate supplier and test the kit against your full product release specification:

• Analytical sensitivity (limit of detection) using serial dilutions of target nucleic acid
• Amplification efficiency from standard curve (for qPCR assays)
• Precision across the measuring range
• Specificity (cross-reactivity panel and exclusivity panel)
• Multiplex performance (if applicable): verify all targets are detected with equivalent sensitivity
• Inclusivity: verify detection of all relevant genotypes/variants

Lot-to-lot comparison. If you are qualifying a second source, perform a side-by-side comparison of oligonucleotides from each supplier in the same kit lot (same enzyme, same master mix, same positive controls). This isolates the oligonucleotide effect from other variables.

Lot-to-Lot Management for Oligonucleotides

Incoming Testing Protocol

Every new oligonucleotide lot should be tested before release to manufacturing:

Level 1 — CoA Review. Verify completeness, accuracy, and compliance with your specification. Confirm lot number, sequence, modifications, purity, concentration, and expiry date match the purchase order and specification.

Level 2 — Analytical Verification. Perform independent confirmation of key parameters:

• Identity by mass spectrometry
• Purity by analytical HPLC or CE
• Concentration by A260
• For dual-labeled probes: verify fluorophore absorbance spectrum and quencher functionality

The depth of analytical verification can be risk-based. For high-volume oligonucleotides used in commercial kits, test every lot. For low-volume oligonucleotides used in development or low-risk assays, a periodic skip-lot testing protocol may be justified with documented risk assessment.

Level 3 — Functional Performance. Test the new lot in the functional assay format:

• For primers: Run the PCR/qPCR assay with the new primer lot and compare amplification efficiency, sensitivity, and specificity to the reference lot
• For probes: Run the qPCR assay with the new probe lot and compare Ct values, fluorescence intensity (ΔRn), and signal-to-noise ratio to the reference lot
• For critical oligonucleotides: Test at limiting target concentration to detect subtle performance differences

Acceptance Criteria for Lot Release

Define quantitative acceptance criteria for each test:

• Purity: Must meet minimum specification (e.g., ≥90% full-length for qPCR primers)
• Identity: Observed mass must match calculated mass within instrument tolerance (typically ±0.5 Da for ESI-MS)
• Concentration: Must be within ±15% of target concentration (or as specified)
• Amplification efficiency: For qPCR primers, standard curve efficiency must be 90-110%, consistent with reference lot
• Ct shift: For qPCR probes, the mean Ct shift at a defined target concentration must not exceed ±0.5 Ct compared to reference lot (tightened to ±0.3 Ct for quantitative assays where small Ct shifts translate to clinically meaningful concentration differences)
• Fluorescence signal: For probes, ΔRn must be within ±20% of reference lot

Handling Lot Failures

If a new oligonucleotide lot fails incoming testing:

1. Confirm the failure by re-testing (eliminate operator and instrument error)
2. If confirmed, quarantine the lot and notify the supplier with full test data
3. Request the supplier's investigation, including their manufacturing records and CoA verification
4. Determine whether the failure affects other lots from the same synthesis campaign
5. Document the failure, investigation, and disposition
6. If the failure represents a trend (multiple lots from the same supplier), escalate to a supplier corrective action request (SCAR)

Contamination Control: The Silent Killer of Molecular Diagnostics

Oligonucleotide contamination is a unique risk in molecular diagnostic manufacturing because the contaminant is amplified by the very assay it contaminates. A single molecule of contaminating amplicon from a previous synthesis run can produce a false positive result in a PCR assay designed to detect a few copies of target. This is fundamentally different from most raw material contamination scenarios, where the contaminant simply adds noise.

Supplier-Level Controls

Evaluate the supplier's contamination prevention practices:

• Physical separation. Synthesis, cleavage/deprotection, purification, and formulation should occur in physically separated areas with independent air handling. Pre-synthesis and post-synthesis operations must not share space.
• Dedicated equipment. Synthesizers, purification systems, and dispensing equipment should be dedicated to specific product types or subjected to validated cleaning procedures between runs.
• Sequence screening. For sequences longer than 55 bases, some suppliers (like LGC Biosearch Technologies) screen for template contamination to ensure that no contaminating template from previous synthesis runs is present in the facility. This is a sophisticated control that not all suppliers implement.
• Negative controls. The supplier should run negative synthesis controls (blank synthesis cycles) at defined intervals to monitor for carryover.

Your Own Manufacturing Controls

Even with a qualified supplier, you must implement contamination controls in your own facility:

• Unidirectional workflow. Separate pre-amplification (reagent preparation, sample preparation) from post-amplification (PCR product handling, analysis) areas. Never move materials or personnel from post-amplification to pre-amplification without decontamination.
• Dedicated equipment and consumables. Pipettes, tips, tubes, and reagents in the pre-amplification area must never be used in the post-amplification area.
• UV decontamination. UV irradiation of work surfaces and equipment between uses.
• Bleach decontamination. Sodium hypochlorite treatment of surfaces and equipment to degrade contaminating DNA.
• No-template controls. Run NTC reactions in every manufacturing batch and every QC release test to monitor for contamination.

Change Notification and Supply Continuity

Types of Changes That Require Notification

The supplier quality agreement should mandate notification for:

• Changes to synthesis chemistry (phosphoramidite supplier, coupling chemistry, deprotection protocol)
• Changes to purification methods or columns
• Changes to synthesis equipment or synthesizer models
• Changes to manufacturing site or facility
• Changes to quality specifications or test methods
• Changes to raw material sources (solvents, reagents, solid supports)
• Changes to storage buffer formulation or lyophilization process
• Discontinuation of specific modification chemistries

Impact Assessment for Supplier Changes

When notified of a change, follow the same impact assessment process used for enzyme supplier changes: obtain detailed before/after information from the supplier, perform analytical and functional testing of post-change material, manufacture a pilot kit lot, test against product release specification, and document the assessment in your change control system.

One scenario specific to oligonucleotides deserves special attention: when a supplier changes their phosphoramidite source. The coupling efficiency and impurity profile of the phosphoramidite directly affect the full-length product yield and the impurity profile of the finished oligonucleotide. A change in phosphoramidite supplier can shift the ratio of full-length to truncated product, change the pattern of side products, and affect downstream assay performance — even if the supplier's CoA still shows the same purity specification, because the purity measurement may not capture all relevant impurities.

Dual Sourcing for Oligonucleotides

Qualifying a second oligonucleotide supplier is more complex than qualifying a second enzyme supplier because oligonucleotide synthesis is inherently less reproducible between manufacturers than protein expression. Different suppliers use different synthesizers, different phosphoramidite lots, different purification protocols, and different analytical methods. The same sequence produced by two suppliers may have slightly different impurity profiles, different concentrations in the supplied formulation, and different functional performance.

The dual-sourcing qualification process requires:

1. Manufacturing the oligonucleotide at both suppliers using identical sequence and modification specifications
2. Performing full analytical characterization of both products
3. Manufacturing pilot kit lots with oligonucleotides from each supplier
4. Performing a cross-over study comparing kit performance between the two oligonucleotide sources
5. Documenting any performance differences and establishing whether they are within acceptable bounds

Some performance differences between suppliers are expected and acceptable. The key is to define the acceptable bounds in advance, based on the assay's performance requirements, and to document the justification for accepting any observed differences.

Regulatory Documentation

For regulatory submissions and audits, maintain the following documentation for oligonucleotide supplier qualification and management:

• Approved supplier list with oligonucleotide suppliers, their quality grade (ISO 13485, GMP), and their qualification status
• Raw material specifications for each oligonucleotide, including sequence, modifications, purity, identity, concentration, contamination limits, and functional performance criteria
• Supplier qualification reports documenting the initial evaluation, analytical verification, functional testing, and approval of each supplier
• Incoming test records for every oligonucleotide lot, with analytical data and functional test results
• Lot-to-lot trending data tracking purity, identity, and functional performance across manufacturing campaigns
• Change control records for supplier-initiated changes, with impact assessments
• Contamination monitoring records including no-template control results from manufacturing and QC
• Stability data for oligonucleotides in storage and in the finished kit formulation
• Supplier quality agreements with change notification clauses, minimum order quantities, and backup supply provisions
• Supplier audit reports from periodic re-audits
• Risk assessments for oligonucleotide supply chain risks, including single-source dependencies and contamination risk

Under EU IVDR, the performance evaluation report for a molecular diagnostic IVD must demonstrate that the assay meets its claimed analytical performance characteristics. Since oligonucleotide quality directly determines analytical sensitivity and specificity, the notified body will expect to see robust supplier qualification and incoming material control as part of the quality management system documentation reviewed during conformity assessment.

Under FDA QMSR, oligonucleotides used in IVD kits are critical raw materials subject to the purchasing controls of ISO 13485 §7.4. FDA inspectors will review incoming material specifications, test records, and change control documentation during facility inspections, and any gaps in oligonucleotide supplier management will be cited as observations.

Practical Recommendations

For IVD manufacturers establishing or improving their oligonucleotide supplier qualification program:

1. Start with the right grade. Use ISO 13485-grade oligonucleotides for all manufacturing, even during development. The cost difference is small compared to the cost of re-qualifying when you transition from research-grade to IVD-grade.

2. Define specifications based on functional impact, not analytical convenience. Purity specifications should be based on how impurity levels affect your assay's performance, not on what the supplier conveniently provides. If your qPCR assay performance degrades below 90% primer purity, your specification should reflect that threshold.

3. Test functionally, not just analytically. Analytical testing confirms identity and purity but does not fully predict functional performance. Every lot should be tested in the functional assay format.

4. Monitor trends, not just pass/fail. Track key parameters (purity, amplification efficiency, Ct values) across lots and look for gradual drift before it hits specification limits. Trend analysis enables proactive supplier engagement before a lot failure occurs.

5. Invest in contamination control at both ends. Your supplier's contamination prevention is your first line of defense, but it cannot substitute for your own facility's contamination control practices. Both are necessary.

6. Qualify a backup supplier before you need one. The lead time to qualify a new oligonucleotide supplier (including pilot kit manufacturing, stability testing, and regulatory notification) is measured in months. By the time your primary supplier has a problem, it is too late to start the qualification process.

7. Include oligonucleotide management in your risk management file. Identify failure modes related to oligonucleotide quality (sequence errors, impurity excursions, contamination, supply disruption) and define the controls that mitigate each risk. This risk-based approach satisfies regulatory expectations and focuses your resources on the highest-impact controls.